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Abstract: Mass spectrometry-enabled ADP-ribosylation workflows are developing rapidly, providing re-
searchers a variety of ADP-ribosylome enrichment strategies and mass spectrometric acquisition options.
Despite the growth spurt in upstream technologies, systematic ADP-ribosyl (ADPr) peptide mass spectral
annotation methods are lacking. HCD-dependent ADP-ribosylome studies are common but the resulting
MS2 spectra are complex, owing to a mixture of b/y-ions and the m/p-ion peaks representing one or
more dissociation events of the ADPr moiety (m-ion) and peptide (p-ion). In particular, p-ions that
dissociate further into one or more fragment ions can dominate HCD spectra but are not recognized by
standard spectral annotation workflows. As a result, annotation strategies that are solely reliant upon
the b/y-ions result in lower spectral scores that in turn reduce the number of reportable ADPr peptides.
To improve the confidence of spectral assignments we implemented an ADPr peptide annotation and
scoring strategy. All MS2 spectra are scored for the ADPr m-ions, but once spectra are assigned as an
ADPr peptide they are further annotated and scored for the p-ions. We implemented this novel workflow
to ADPr peptides enriched from the liver and spleen isolated from mice post 4-hour exposure to systemic
IFN-฀. HCD collision energy experiments were first performed on the Orbitrap Fusion Lumos and the
Q Exactive, with notable ADPr peptide dissociation properties verified with CID (Lumos). The m-ion
and p-ion series score distributions revealed that ADPr peptide dissociation properties vary markedly be-
tween instruments and within instrument collision energy settings, with consequences on ADPr peptide
reporting and amino acid localization. Consequentially, we increased the number of reportable ADPr
peptides by 25% (liver) and 17% (spleen) by validation and the inclusion of lower confidence ADPr pep-
tide spectra. This systematic annotation strategy will streamline future reporting of ADPr peptides that
have been sequenced using any HCD/CID-based method.
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Abstract  1 
Mass spectrometry-enabled ADP-ribosylation workflows are developing rapidly, providing researchers a 2 
variety of ADP-ribosylome enrichment strategies and mass spectrometric acquisition options. Despite the 3 
growth spurt in upstream technologies, systematic ADP-ribosyl (ADPr) peptide mass spectral annotation 4 
methods are lacking. HCD-dependent ADP-ribosylome studies are common but the resulting MS2 5 
spectra are complex, owing to a mixture of b/y-ions and the m/p-ion peaks representing one or more 6 
dissociation events of the ADPr moiety (m-ion) and peptide (p-ion). In particular, p-ions that dissociate 7 
further into one or more fragment ions can dominate HCD spectra but are not recognized by standard 8 
spectral annotation workflows. As a result, annotation strategies that are solely reliant upon the b/y-ions 9 
result in lower spectral scores that in turn reduce the number of reportable ADPr peptides. To improve 10 
the confidence of spectral assignments we implemented an ADPr peptide annotation and scoring 11 
strategy. All MS2 spectra are scored for the ADPr m-ions, but once spectra are assigned as an ADPr 12 
peptide they are further annotated and scored for the p-ions. We implemented this novel workflow to 13 
ADPr peptides enriched from the liver and spleen isolated from mice post 4-hour exposure to systemic 14 
IFN-. HCD collision energy experiments were first performed on the Orbitrap Fusion Lumos and the Q 15 
Exactive, with notable ADPr peptide dissociation properties verified with CID (Lumos). The m-ion and p-16 
ion series score distributions revealed that ADPr peptide dissociation properties vary markedly between 17 
instruments and within instrument collision energy settings, with consequences on ADPr peptide 18 
reporting and amino acid localization. Consequentially, we increased the number of reportable ADPr 19 
peptides by 25% (liver) and 17% (spleen) by validation and the inclusion of lower confidence ADPr 20 
peptide spectra. This systematic annotation strategy will streamline future reporting of ADPr peptides that 21 
have been sequenced using any HCD/CID-based method. 22 
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Introduction 1 
ADP-ribosylation is a posttranslational modification (PTM) that is catalyzed by the polyadenosine 2 
diphosphate-ribose polymerase (PARP) enzyme family; also referred to as the diphtheria toxin-like ADP-3 
ribosyl transferases (ARTDs) (1). The PARPs catalyze the transfer of the ADP-ribosyl (ADPr) moiety of 4 
NAD to proteins targets, whose amino acid acceptor sites have been identified as primarily aspartate, 5 
glutamate, lysine, arginine and serine; but also, threonine, tyrosine, histidine and cysteine (2-5). The 6 
ubiquity of protein ADP-ribosylation is becoming more apparent as the mass spectrometry-based 7 
workflows used to identify ADP-ribosylated proteins continue to improve. ADP-ribosylome studies are of 8 
growing interest since the PARP enzymes are implicated in a variety of cellular functions, such as 9 
oxidative stress and DNA repair (6), RNA biology (7), and host-pathogen interactions and inflammation 10 
(7, 8). As a consequence of their broad roles in biology, the PARP substrate pool is likely vaster than 11 
what has already been reported (8). 12 
There is an assortment of wet lab and mass spectrometry workflows available to study ADP-13 
ribosylation. Proteins can be mono-ADP-ribosylated (MARylated) or poly-ADP-ribosylated (PARylated) 14 
(9), but only hydrolyzed forms of the PTM, for example the conversion of PAR to MAR peptides using 15 
poly-ADP-ribose glycohydrolase (PARG) (2, 10, 11) and the conversion of PAR/MAR to a phosphoribose 16 
using a phosphodiesterase (12), are conducive to mass spectrometry. As of late, MARylation-based 17 
enrichment studies are gaining traction since ADPr peptides produce diagnostic MS2 fragment ions that 18 
can be used to increase confidence that spectra contain modified peptides (13-15). The ADP-ribose is 19 
labile with collision induced dissociation (CID) and higher energy induced dissociation (HCD); producing 20 
lower mass fragments from the ADP-ribose moiety (m-ions) and the complementary peptide plus 21 
remaining ADP-ribose fragment (p-ions) (13).  22 
Despite the convenience of diagnostic ions, ADPr peptides exhibit complex fragmentation 23 
properties, requiring more than one dissociation method for their annotation. CID for instance produces 24 
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peptide sequencing. On the other hand, sequential dissociation provided by HCD increases the 1 
prevalence of backbone fragments (14), but also promotes dissociation of the peptide precursor p-ions 2 
into fragment p-ions. This sequential dissociation increases the complexity of MS2 spectra to be 3 
interpreted since MS2 sequencing algorithms do not readily recognize p-ions, other than the p-ion 4 
corresponding to the complete loss of the ADPr modification. Candidate ADPr spectra and acceptor sites 5 
are validated by either manual inspection or by supplemented scripts that confirm the presence of p-ions 6 
(3, 11). Electron capture and transfer dissociation (ECD, ETD) (13, 16) retain the intact ADP-ribose on 7 
the acceptor amino acid, which is amenable to acceptor site localization. However, these dissociation 8 
methods are slower than HCD, reducing the number of candidate ADPr peptide spectra to be analyzed. 9 
Moreover, they work best with highly charged ADPr peptides (14). Very recently, infrared photo-activation 10 
ionization (AI)-ETD was demonstrated to outperform HCD as a supplemented activation method to 11 
analyze MARylated peptides (17). Studies enriching MARylated peptides thus leverage the pros of each 12 
method and employ various dissociations strategies or combinations thereof (eg., EThcD) to maximize 13 
ADPr peptide sequencing (2, 11, 14).   14 
We previously reported the ADP-ribosylome of the human macrophage cell-like line THP-1 15 
stimulated with or without the proinflammatory cytokine IFN-(11). Our particular interests in macrophage 16 
ADP-ribosylation stemmed from our earlier report describing PARP14 and PARP9 as novel IFN- 17 
inducible proteins and potential regulators of pro-inflammatory activation (18). IFN--stimulated THP-1 18 
cells also resulted in an increase in the ADP-ribosylation status of PARP14 and PARP9, and several 19 
ribosomal and heat shock proteins (11). In the THP-1 ADP-ribosylome study, we employed the 20 
MARylation enrichment strategy. To further enrich for ADPr peptides within the mass spectrometer, we 21 
applied an m-ion-dependent triggered strategy that employed a fast (lower-end resolution, higher-end 22 
collision energy) HCD scan to screen for diagnostic m-ions that if detected was followed by alternating 23 
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acquisition strategy therefore ensured that each precursor ADPr peptide would benefit from both HCD 1 
and EThcD dissociation methods.  2 
Despite the prevalence of ADPr diagnostic m-ions and p-ions in the MS2 spectra, we and others 3 
have been limited to standard peptide scoring algorithms and confidence scores to identify and report 4 
ADPr peptides. However, there is great potential in implementing a fragment p-ion scoring strategy to 5 
supplement b/y-ion annotation methods. Fragment p-ions are prevalent in HCD MS2 spectra but 6 
represent complex peaks owing to dissociation of both the backbone peptide and the ADPr PTM (15). 7 
Nonetheless, fragment p-ions harbor information for peptide and amino acid acceptor site identification 8 
but are not considered in standard peptide scoring workflows; thereby under-utilizing the full potential of 9 
ADPr peptide spectral features.  10 
In this current study, we have developed a novel ADPr spectrum annotation workflow that 11 
overcomes the caveats of relying on standard spectral annotation algorithms to score ADPr spectra. The 12 
ADPr annotation workflow comprises an m-ion series score and a p-ion series score that are used to 13 
identify and validate candidate ADPr MS2 spectra, respectively. We applied this new ADPr annotation 14 
workflow to analyze the ADP-ribosylome from liver and spleen isolated from mice post an IFN--induced 15 
pro-inflammatory response. Using a subset of liver samples, we first performed several mass 16 
spectrometric acquisition optimization trials, performed on the Orbitrap Fusion Lumos (HCD, CID) and Q 17 
Exactive (HCD), that monitored the impact of the m-ion and p-ion series scores on the outcome of ADPr 18 
spectral annotation. Once optimal spectral annotation strategies and confidence thresholds were 19 
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Experimental Procedures 1 
Experimental Design and Statistical Rationale  2 
A pilot IFN- (vs. saline) dosing and time course study was done to establish optimal treatment conditions 3 
(n=2 mice per condition and dose and time point for liver and spleen). The remaining liver samples were 4 
used to prepare a pilot ADPr peptide pool to perform collision energy experiments; and spleen pilot 5 
samples were used to perform targeted MS2 (tMS2) validations.  For the main mouse infusion 6 
experiments performed in this study (Fig. 1A), a total of seven male mice per group (no treatment control, 7 
saline, and IFN-) were compared for RT-PCR, but n=6 were used per group for proteomics. Male mice 8 
alone were chosen to eliminate potential variation due to sex. Protein yields (10 mg) from liver portions 9 
were sufficient to analyze each liver separately (n=6 per group), however, two spleens had to be pooled 10 
resulting (n=3 per group) to be compared. Pooling spleens was supported by the verification that IFN- 11 
elicited a response in all six mice, as determined by monitoring prototypical IFN--responsive genes 12 
(presented in the latter half of the study).  13 
 14 
Mouse Infusions  15 
All animal procedures used in this study were approved by and performed in compliance with Beth Israel 16 
Deaconess Medical Center’s Institutional Animal Care and Use Committee (protocol #: 021-2017). Male 17 
C57BL/6J mice (10 weeks old, The Jackson Laboratory, Bar Harbor, ME, Cat# 000664) were treated with 18 
either IFN- (100 K units/mouse, 1.0 mL, R&D Systems, Minneapolis, MN, Cat# 485-MI-100) or saline 19 
(1.0 ml, Owens & Minor, Mechanicsville, VA, Cat# 85583) through intraperitoneal injection, and then an 20 
analgesic (buprenorphine, 1.2 mg/kg, Henry Schein Animal Health, Melville, NY, Cat# 1217793) was 21 
given by subcutaneous injection. At four hours they were sacrificed in a CO2 chamber. The mice were 22 
perfused with 10 ml of a PARP/PARG inhibitory buffer [1.0 µM PJ-34 (Millipore Sigma, Burlington, MA, 23 
Cat# 528150), 250 nM ADP-HPD (Millipore Sigma, Cat# 118415), phosphate buffered saline (PBS, 24 
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gently washed with PBS. Each tissue was divided into two, with the majority for Western blot analysis 1 
and Proteolysis for proteomic analysis (see below), and a smaller portion sufficient for Real-time PCR 2 
(below). 3 
 4 
Tissue Harvest and Homogenization 5 
Each tissue was transferred to a Precellys 2 ml tube from the Soft Tissue Homogenizing Ceramic Beads 6 
Kit (Bertin Technologies, Montigny-le-Bretonneux, France, Cat# CK14). TRIzol (0.5 ml, Thermo Fisher 7 
Scientific, Waltham, MA, Cat# 15596-018) was added to tissues for real-time-PCR. A modified RIPA 8 
buffer [0.5 mL, 50 mM Tris-HCl pH 7.4 (Boston BioProducts, Ashland, MA, Cat# BM-327), 0.4 M NaCl 9 
(Sigma-Aldrich, St. Louis, MO, Cat# S9888), 1.0 mM EDTA (Boston Bio Products, Cat# BM-150), 1.0% 10 
nonidet P-40 (Sigma-Aldrich, Cat# 74385), 0.1% sodium deoxycholate (Sigma-Aldrich, Cat# D6750), 40 11 
µM PJ34, 1.0 µM ADP-HPD, protease inhibitor cocktail (Sigma-Aldrich, Cat# P8340), phosphatase 12 
inhibitor (Sigma-Aldrich, Cat# 4906845001)] (10) was added to tissues for protein analysis. Tissues were 13 
homogenized in a Precellys 24 Tissue Homogenizer (Bertin Technologies, Cat# P000669-PR240-A) 14 
using three 10 second cycles at 5,000 rpm that were then cooled on ice for 15 minutes. The tissue debris 15 
were then removed by centrifugation (3,000 rpm, 4 oC, 5 minutes).  16 
 17 
Experiments to Confirm IFN- Elicited a Proinflammatory Response in Mice 18 
1) Real-time PCR - Reverse transcription was performed using qScript cDNA Synthesis Kit (QuantaBio).  19 
The mRNA expression was determined by 7900 HT Fast Real time PCR System (Thermo Fishcer 20 
Scientific). Master mix for Real time PCR was PerfeCTa® qPCR FastMix II, ROX (VWR International, 21 
Radnor, PA, Cat# 97065-998), and TaqMan probes were used as follows: human GAPDH 22 
(Hs02758991_g1, Life Technologies), human PARP14 (Hs00981511_m1), human IL-1β 23 
(Hs00174097_m1), human CCL2 (Hs00234140_m1), human CXCL9 (Hs00171065_m1), human 24 
CXCL10 (Hs01124252_g1), human CXCL11 (Hs04187682_g1). The expression levels were normalized 25 
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using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Cat# 23225). One milligram of protein 1 
(diluted into 100 ul modified RIPA buffer) was mixed with 20 ul 6X SDS-Sample Buffer (Boston Bio 2 
Products, Cat# BP-111R) and boiled at 95 oC for 5 minutes. The denatured samples were separated by 3 
SDS-PAGE [8.0% acrylamide (Boston Bio Products, Cat# BAC-30PA), BAC-30PA (Boston Bio Products, 4 
Cat# BP-90), stacking buffer (Boston Bio Products, Cat# BP-95), N,N,N',N'-tetramethylethylenediamine 5 
(TEMED, Sigma-Aldrich, Cat# 1610801), ammonium persulfate (Sigma-Aldrich, Cat# A3678-25G)] and 6 
transferred to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA, Cat# 1620112). The 7 
membranes were blocked with 2.5% non-fat dry milk (Santa Cruz Biotechnolgy, TX, Cat# sc-2325) in 1X 8 
tris-buffered saline with 0.1% Tween 20 (TBST, Boston BioProducts, MA, Cat# IBB-181). The following 9 
primary antibodies were used: a human ARTD8/PARP14 antibody (1:1000, Santa Cruz Biotechnology, 10 
Cat# sc-377150); a pan ADP-ribose reagent (1:300, Millipore Sigma, Cat# MABE1016); a β-actin 11 
antibody (1:5000, Novus Biologicals, LLC, CO, Cat# NB600-501). The secondary antibodies were anti-12 
mouse peroxidase conjugate (1:5000, Sigma-Aldrich, Cat# A4416-1ML) and anti-rabbit peroxidase 13 
conjugate (1:5000, Sigma-Aldrich, Cat# A0545-1ML) as required for the primary antibodies and detected 14 
using Clarity Western ECL blotting substrate (Bio-Rad Laboratories, Cat# 1705060) and imaged using 15 
ImageQuant LAS 4000 (GE Healthcare). 16 
 17 
Proteolysis Steps 18 
For protein precipitation, acetone (Fisher Scientific, Hampton, NH, Cat# A949-1) was added to the tissue 19 
homogenates (10) and then resuspended in a denaturation buffer [6.0 M urea (Sigma-Aldrich, Cat# 20 
U4884), 2.0 M thiourea (Sigma-Aldrich, Cat# T7875), 10 mM HEPES (Boston BioProducts, Cat# BBH-21 
75-K)]. The protein amount was determined by a Pierce 660 nm Protein Assay Reagent (Thermo Fischer 22 
Scientific, Cat# 22660). Proteins (5.0-10 mg, two spleen tissues were merged) were reduced in 1.0 mM 23 
dithiothreitol (DTT, Thermo Fisher Scientific, Cat# 20290) and alkylated in 5.5 mM chloroacetamide 24 
(Sigma-Aldrich, Cat# C0267). Proteolysis was performed with LysC for 4 hours, followed by trypsin 25 
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mM ammonium bicarbonate (Sigma-Aldrich, Cat# 09830) overnight. The peptides were desalted using 1 
Sep-Pak C18 Classic Cartridge (Waters, Milford, MA, Cat# WAT051910) by following the manufacturer’s 2 
instructions. Using a Concentrator plus complete system (Eppendorf AG, Hamburg, Germany, Cat# 3 
5305000304), the peptide sample was reduced to a final volume of 0.8 ml of affinity precipitation buffer 4 
[50 mM Tris-HCl pH 7.4, 10 mM MgCl2 (Sigma-Aldrich, Cat# 63069), 250 µM DTT, 50 mM NaCl]. Peptide 5 
amount was determined by using a NanoDrop2000 Spectrophotometer at 280 nm (Thermo Fisher 6 
Scientific). One hundred microgram input peptide was set aside to measure the proteome, whereas 3.0-7 
4.0 mg of peptide was used for the eAf1521 enrichment protocol. 8 
 9 
eAf1521 Macrodomain Removal and Peptide Recovery  10 
We used the recently engineered Archaeoglobus fulgidus macrodomain (eAf1521) (19) to enrich 11 
MARylated peptides. Expression and purification steps were done according to a published protocol (10). 12 
However, this study includes further optimization of this protocol, by removing the eAf1521 from the 13 
enriched ADPr peptides. eAf1521 (47 kDa) done using a molecular weight cut off (MWCO) filter cartridge, 14 
the Microcon-30 kDa Centrifugal Filter Unit (Millipore Sigma, Cat# MRCF0R03).  15 
MWCO cartridges 1 to 4 (supplemental Fig. S1) were equilibrated by passing 300 μl of 20% 16 
acetonitrile (Fisher Scientific, Cat# A955-1) /LC-MS-grade water (Fisher Scientific, Cat# W6-1) twice, 300 17 
μl of 0.1 mol/l NaOH (Honeywell International, Charlotte, NC, Cat# 71463 Fluka) twice, 300 μl of LC/MS-18 
grade water twice, and 300 μl of 0.15% trifluoroacetic acid (TFA, Sigma Aldrich, Cat# 302031) three times 19 
(14,000 rpm, 5 minutes). MWCO cartridge 5 was equilibrated by following a published protocol (2). 20 
As a proof-of-concept that the eAf1521 is retained by the cartridge while peptides are recovered, 21 
we performed the following experiments. The free eAf1521 macrodomain (from 50 μl of the conjugates, 22 
(10)) or Pierce HeLa Protein Digest Standard (1.0 μg, Thermo Fisher Scientific, Cat# 88328) was used 23 
as input into each equilibrated MWCO cartridge. The input samples were diluted in 0.15% TFA (total 24 
volume 300 μl) and passed through each cartridge (14,000 rpm, 10 minutes). An additional 0.15% TFA 25 
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were collected to new tubes (low protein binding collection tubes, Thermo Fisher Scientific, Cat# 90411). 1 
The samples were dried down using a tabletop speed vacuum (60 oC, 2 hrs, Thermo Fisher Scientific, 2 
Cat# SPD1010). The flow-through and retained fractions for the eAf1521 experiment were resuspended 3 
in 1X SDS-sample buffer (Boston Bio Products, Cat# BP-111R) and boiled at 95 oC for 5 minutes for 4 
SDS-PAGE (Mini-PROTEAN TGX Precast Protein Gels, Bio-Rad Laboratories, Hercules, CA, Cat# 5 
4561094, Precision Plus Protein Dual Color Standards, Bio-Rad Laboratories, Cat# 161-0394, Tris-6 
Glycine-SDS Running Buffer, Boston BioProducts, Cat# BP-150). The gel was stained with Bio-Safe 7 
Coomassie Stain (Bio-Rad Laboratories, Cat# 1610786) by following the instructions. The flow-through 8 
and retained fractions for HeLa standard peptides were resuspended in loading buffer [5.0% acetonitrile 9 
(Fisher Scientific, Cat# A955-1), 0.5% formic acid (Thermo Fisher Scientific, Cat# 28905) in water (Fisher 10 
Scientific, Cat# W6-1)] for LC-MS/MS analysis. The Micron cartridge peptide flow-through is most similar 11 
to input, indicating optimal and ideal recovery of peptides (supplemental Fig. S2). 12 
The MS2 data from the HeLa digests were queried against the human UniProt database 13 
(downloaded on November 2018; 155,133 entries) using the SEQUEST-HT search algorithm, via the 14 
Proteome Discoverer (PD) Package (version 2.2, Thermo Fisher Scientific), using a 10 ppm tolerance 15 
window in the MS1 search space, and a 0.02 Da fragment tolerance window for HCD. Trypsin (full) was 16 
set as the digestion enzyme, allowing up to 4 missed cleavages and a minimum peptide length of 6 amino 17 
acids. Oxidation of methionine was set as a variable modification and carbamidomethylation of cysteine 18 
was set as a fixed modification. The peptide false discovery rate (FDR) was calculated using Percolator 19 
provided by PD and peptides were filtered based on a 1.0% FDR. Peptides assigned to a given protein 20 
group, and not present in any other protein group, were considered as unique. Consequently, each 21 
protein group is represented by a single master protein (PD grouping feature). Master proteins with two 22 
or more unique peptides were used for precursor ion intensity-based quantification. Statistical analysis 23 
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eAf1521-Dependent Enrichment of MARylated Peptides 1 
Expression and purification of the eAf1521 macrodomain were done according to a published (10). The 2 
peptide mixture was treated with PARG overnight (1.0 μg PARG per 1.0 mg peptide, Creative BioMart, 3 
Shirley, NY, Cat# PARG-31H) to obtain only MARylated peptides (2), and the peptides were enriched 4 
using the macrodomain affinity pull-down as described previously (10). Eighty percent of eluted ADPr 5 
peptides were processed using the MWCO filtration step using the Microcon-30kDa Centrifugal Filter 6 
Unit, Millipore Sigma, Cat# MRCF0R03 (see eAf1521 macrodomain removal and peptide recovery). The 7 
peptides were desalted using Oasis HLB cartridge [10 mg (Waters, 1 cc, Cat# 186008055) for the input 8 
peptides; 30 mg (Waters, 1 cc, Cat# WAT094225) for the MARylated peptides] by following its instruction 9 
and suspended in loading buffer [5.0% acetonitrile (Fisher Scientific, Cat# A955-1), 0.5% formic acid 10 
(Thermo Fisher Scientific, Cat# 28905) in water (Fisher Scientific, Cat# W6-1)] for LC-MS/MS analysis. 11 
 12 
LC-MS/MS 13 
ADPr (MARylated) peptides from control, saline, and IFN- elicited mouse tissues (spleen and liver) were 14 
analyzed using the Orbitrap Fusion Lumos fronted with an EASY-Spray Source, coupled to an Easy-15 
nLC1000 HPLC pump (Thermo Fisher Scientific), and the Q Exactive Orbitrap (+ Easy-nLC1000) fronted 16 
with a Nanospray FLEX ion source (Thermo Fisher Scientific). Lumos collision energy experiments – 17 
A pool of mouse liver ADPr peptides from the pilot study were subjected to a dual column set-up: an 18 
Acclaim PepMap RSLC C18 trap column, 75 µm X 20 mm (Thermo Fisher Scientific, Cat# 164261); and 19 
an EASY-Spray LC Column, 75 µm X 250 mm (Thermo Fisher Scientific, Cat# ES802A). The analytical 20 
gradient for the ADPr peptide pool was run at 300 nl/min from 5 to 21 % Solvent B (acetonitrile/0.1% 21 
formic acid) for 50 minutes, followed by ten minutes of 21 to 30% Solvent B, and another 10 minutes of 22 
a jigsaw wash (alternating between 5 and 95% Solvent B) to clean the column. Solvent A was water/0.1% 23 
formic acid. The instrument was set to 120 K resolution and the top N precursor ions (within a scan range 24 
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seconds), the isolation width was m/z 1.2, and the resolution was 120 K (automatic gain control, AGC, 1 
1.0e4). HCD collision energies were set to, 20%, 24%, 26%, 28%, 30%, 32% or 34%. The CID collision 2 
energy settings were 20%, 24%, 26%, 28%, 30%, 32%, 34%, 36% and 40%. Q Exactive collision 3 
energy experiments – A pool of mouse liver ADPr peptides from the pilot study were subjected to a dual 4 
column set-up: an Acclaim PepMap RSLC C18 trap column, 75 µm X 20 mm (Thermo Fisher Scientific, 5 
Cat# 164261); and an Acclaim PepMap 100 C18 HPLC column, 75 µm X 250 mm (Thermo Fisher 6 
Scientific, Cat# 164941). The analytical gradient for the ADPr peptide pool was run at 300 nl/min from 5 7 
to 21 % Solvent B (acetonitrile/0.1% formic acid) for 50 minutes, followed by ten minutes of 21 to 30% 8 
Solvent B, and another 10 minutes of a jigsaw wash. The instrument was set to 70 K resolution (AGC 9 
target, 3e6), and the top 10 precursor ions (within a scan range of m/z 400-1500) were subjected to HCD 10 
isolation width m/z 1.6, dynamic exclusion enabled (60 seconds), and resolution set to 140 K (AGC target, 11 
5e4). The HCD collision energies were set to, 20%, 24%, 26%, 28%, 30%, 32% or 34%.  Lumos-12 
dependent analysis of IFN--elicited mouse liver and spleen ADPr peptides - The ADP-ribose 13 
product ion triggered method was applied (11, 20). The chromatographic conditions were the same as 14 
the Lumos collision energy experiments. The m-ion product scan employed data-dependent HCD 15 
acquisition (collision energy 30% +/- 2.5%, isolation width m/z 1.2, scan range m/z 120-445 to capture 16 
only the m-ions, and resolution set to 30 K). When two or more ADP-ribose fragment ions (m/z 136.0623, 17 
250.0940, 348.0709, and 428.0372) were detected, alternating HCD (CE 27.5% +/- 2.5%; resolution 120 18 
K) and EThcD (calibrated charge dependent ETD parameters enabled, supplemental activation collision 19 
energy 22.5%, and resolution 120 K) scans were triggered. Each ADPr peptide sample was injected five 20 
times (n=6 for control, saline and IFN- liver; n= 3 for control, saline and IFN- spleen). eAf1521 input 21 
peptides (input proteome) were analyzed using the data-dependent HCD acquisition (resolution 30 K for 22 
MS/MS) but without triggered data acquisitions. A summary of all acquisition strategies is provided in the 23 
supporting information (supplemental Fig. S3). Scheduled targeted MS of the PARP14 ADPr peptide 24 
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energy experiments above. The PARP14 ADPr peptide (HISGLAQALSK + ADP-ribose, m/z 555.9058, 1 
z=3) was analyzed using either HCD alone (CE20 or CE22%; resolution 120 K), or using HCD (CE 28% 2 
+/- 3%; resolution 120 K) and EThcD on the same precursor (calibrated charge dependent ETD 3 
parameters enabled, supplemental activation collision energy 22.5%, and resolution 120 K).  4 
 5 
ADP-ribosylation p-series and m-series Scores 6 
The ADP-ribosylation p-series and m-series (Fig. 1B, supplemental Table S1) scores were calculated as 7 
follows: 8 
m − series score = ∑ (𝐼𝑘𝐼𝑏 ∗ 100) /𝑛
𝑛
𝑘=1  9 
𝑚𝑖 ion score = 𝐼𝑖𝐼𝑏 ∗ 100 10 
Where, 11 
𝑘 is the index,  12 
𝑛 is the total number of ions considered,  13 
𝑖 is the ion number (1,3,6 and 8),  14 
𝐼𝑘 is the absolute intensity of a given m-ion, 15 
𝐼𝑏 is the base peak intensity. 16 
p − series score = ∑ (𝐼𝑘𝐼𝑏 ∗ 100) ∗ 𝑘
𝑛
𝑘=1  17 
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Where, 1 
𝑘 is the index,  2 
𝑖 is the ion number (1,3,5,8 and 10),  3 
𝐼𝑘 is the absolute intensity of a given p-ion,  4 
𝐼𝑏 is the base peak intensity.  5 
For the m-series score, the m1, m3, m6 and m8-ions yielded the most intense signal intensities as 6 
determined from ADPr peptide spectra collected with varying HCD collision energies; thus were included 7 
for the score.  For the p-series score calculation, 𝐼𝑘 was always larger than 𝐼𝑘−1 and the individual scores 8 
were also calculated on this sorted list. The main p-series score was also optionally used as a feature for 9 
Percolator peptide validation. 10 
 11 
Standard MS/MS Spectral Annotation 12 
ADPr samples’ mass spectra were analyzed using a customized ADPr annotation and scoring module 13 
developed internally as an enhancement for Proteome Discoverer (PD version 2.4, Thermo Fisher 14 
Scientific). Spectral processing steps that were in common to most analyses were as follows: The 15 
spectra were queried against the Uniprot mouse (n=63,703 entries) database (downloaded September 16 
09, 2020) using the SEQUEST-HT algorithm. Trypsin (full) was set as the digestion enzyme, allowing up 17 
to 4 missed cleavages and a minimum peptide length of 6 amino acids. ADPr (+541.061 Da) of Asp, Glu, 18 
Lys, Arg, Ser, Thr, Tyr and His; oxidation (+15.995 Da) of methionine; and acetylation (+42.011 Da) of 19 
the N-terminus, were set as variable modifications. Carbamidomethylation (+57.021 Da) of cysteine was 20 
set as a static modification. To note, a sampled analysis of ADPr data using carbamidomethylation and 21 
ADPr of Cys as variable modifications did not yield any ADPr-cysteine modified peptides; thus, the Cys 22 
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for the precursor mass and 20 mmu (all HCD, EThcD and CID products were measured in the Orbitrap). 1 
The peptide false discovery rate (FDR) was calculated using Percolator (target/decoy method, separate 2 
databases) and spectra were filtered based on a 1.0% or 5.0% FDR, as indicated. The ‘p-series score’ 3 
was calculated in order to validate candidate spectra identified by SEQUEST. Subsequent XCorr 4 
thresholds for p-series scores-supported spectra were based on recommended medium confidence cut-5 
offs in the ‘Fixed PSM Scorer’ Node in PD (z=2, 0.8; z=3, 1.0; z≥4, 1.2).  Peptide-spectrum match (PSM) 6 
ranks pertains to the SEQUEST search engine rank. The proteome samples’ (input peptides into ADPr 7 
workflow that were set aside) mass spectra were analyzed as above with the notable exceptions: ADPr 8 
modification was not considered, the spectra were filtered based on a 1.0% FDR cut-off, and proteins 9 
with 2 or more unique peptides were considered.   10 
 11 
Isolation Interference 12 
Percent isolation interference was calculated using PD2.4 (details in the user manual). The calculation is 13 
used only for high resolution and accuracy scans:  14 
% isolation interference = 100 x [1 − ( precursor intensity in isolation windowtotal intensity in isolation window )] 15 
 16 
Feature Alignment for Relative Quantification Analysis  17 
Relative quantification was performed by the Feature Mapper and Precursor Ions Quantifier nodes. The 18 
maximum retention time shift for chromatographic alignments was set to 10 minutes and the mass 19 
tolerance was set to 10 ppm. Feature linking and mapping retention time tolerance was 0, and mass 20 
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Amino Acceptor Site Analysis 1 
EThcD scans of the m/z 400-1500 acquisitions (n=6 per treatment group in liver, for a total of 18 .raw 2 
files; n=3 per treatment group in spleen, for a total of 9 .raw files) were the input files the amino acid 3 
acceptor site profiling using the ‘IMP-ptmRS’ node in PD2.4. High confidence search engine rank 1 ADPr 4 
peptides (Protein Group = 1) were considered. The highest probability acceptor site is reported per 5 
peptide, with a minimum probability of 95%, is reported.  6 
 7 
Reprocessing of Unidentified MS2 Spectra  8 
ADPr samples’ MS/MS spectra yielding ‘0 PSMs’ (unidentified spectra) using the standard search 9 
parameters above were exported from Proteome Discoverer as .mzML files. For the HCD collision energy 10 
experiments we considered the possibility that some of these spectra may be atypical tryptic peptides 11 
thus we used semi-trypsin as a search parameter and decreased the number of amino acids to four. 12 
When exporting unidentified HCD spectra, only those with m-series scores ≥30 were included.  13 
 14 
Network Analysis 15 
To generate protein-protein interaction networks, proteins lists were entered into the online STRING 16 
Database version 11(21). For both liver and spleen queries, the full network and all the interaction sources 17 
(text mining, neighborhood, experiments, gene fusion databases, co-occurrences and co-expression) 18 
were activated. Each network edge indicates a confidence level: the minimum required interaction score 19 
for liver was set to 0.9, the highest confidence; and for spleen it was set to 0.5, medium confidence, since 20 
the number of spleen ADPr proteins was too few for a stricter threshold. We also performed k-means 21 
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using the EnrichR database (22). Adjusted p-values provided by EnrichR were calculated by the Fisher’s 1 
exact test. 2 
 3 
Statistical Analysis 4 
Statistical analyses for RT-PCR data were performed using Prism (version 5.04, GraphPad Software, 5 
CA). Unpaired t-tests with Welch’s correction were used to make statistical comparison between saline 6 
and IFN-γ group. Relative proteome and ADPr peptide abundances were analysed using the statistical 7 
software, Qlucore (version 3.5, Sweden). Each analysis comparing the changes to either the proteome 8 
or ADPr peptide abundances for liver and spleen, employed a two-group comparison between saline and 9 
IFN-. For the liver, variances due to ADPr enrichment batches were removed from the analysis, before 10 
applying the comparison. We performed infusion, sacrifices and organ harvest for all mice, n=6 per group, 11 
in a single day. However, for liver samples, the ADPr enrichment was prepared in two batches (n=3 per 12 
group per batch/separate weeks). The two-group comparisons involving liver samples therefore required 13 
an elimination of variables due to sample preparation batch effects. The three spleen samples (2 pooled 14 
spleens per sample per group) were prepared at the same time thus there were no ADPr enrichment 15 
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Results 1 
A Complete Workflow for ADP-ribosylation Proteomics  2 
Even though ADP-ribosylation proteomics is increasing in feasibility in the wet lab, systematic and 3 
streamlined computational methods to annotate and assess the quality of ADPr spectra do not exist. In 4 
the context IFN--induced changes to mouse liver and spleen ADP-ribosylomes, we developed a set of 5 
novel ADPr annotation scores implemented as an enhancement to Proteome Discoverer 2.4. These 6 
scores are readily incorporated into standard mass spectral annotation workflows (Fig. 1). As a source 7 
of ADPr peptides we established an acute IFN--induced pro-inflammatory response in mice to assess 8 
the changes of the ADP-ribosylome in liver and spleen tissues (Fig. 1A). In addition, we modified our 9 
ADPr peptide enrichment strategy by using a newly engineered Af1521 macrodomain (eAf1521) (19) to 10 
enrich MARylated peptides; and added a molecular weight cut-off filter as an ADPr peptide cleaning step 11 
(supplemental Figs. S1 and S2). Using primarily the quadrupole ion-trap Orbitrap Fusion Lumos but also 12 
the quadrupole Orbitrap Q Exactive, we ran pilot studies using mouse liver ADPr peptides to establish 13 
the ADPr peptide annotation node. The dissociation properties of ADPr peptides have already been 14 
determined (13). The low mass ‘m-ions’ are derived from the ADP-ribose and the complementary ‘p-ions’ 15 
comprise the peptide plus remaining ADPr modification (Fig. 1B, C). The corresponding m-ion and p-ion 16 
series annotations and scores (Experimental Section, ADP-ribosylation p-series and m-series scores) 17 
are implemented once candidate ADPr spectra are assigned and scored by the search engine (in this 18 
case SEQUEST-HT) (Fig. 1D).  19 
The availability of the m-ion and p-ion scoring strategy permitted us to not only provide a means 20 
to evaluate and validate candidate ADPr spectra, but also to monitor and elucidate further the dissociation 21 
properties of ADPr peptides. In the following sections, we report how various instrument acquisition 22 
methods impact the number of annotated ADPr spectra. As importantly however, we have come to 23 
understand how the corresponding m-ion and p-ion dissociation dynamics influence these annotations, 24 
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 1 
ADPr Spectral Confidence Reporting is Challenged by Low XCorr Values 2 
Using the pilot mouse liver ADPr peptide pool we first explored the dependency on dissociation method, 3 
collision energy, and instrument platform (supplemental Fig. S3) on the yield of ADPr peptide spectrum 4 
matches (PSMs). The proportion of annotated rank1 ADPr spectra (5% FDR) averaged between 4% 5 
(CID) to 14% (HCD, Lumos), and rank1 non-ADPr spectra between 34% (CID) and 40% (HCD, Q 6 
Exactive) (Fig. 2A). Unidentified spectra ranged between 50% (HCD, Lumos) to 62% (CID) (Fig. 2A). 7 
Increasing HCD collision energy on the Lumos, especially after collision energy (CE) 26%, increased the 8 
number of ADPr and non-ADPr spectra (or PSMs) (Fig. 2A). On the other hand, increasing collision 9 
energy on the Q Exactive increased the number of ADPr spectra up to CE 26%, but then those numbers 10 
decreased steadily until CE 34% (Fig. 2A). Non-ADPr spectra were relatively stable on the Q Exactive, 11 
but their numbers declined at higher collision energies (Fig. 2A). Increasing CID collision energy 12 
increased the number of annotated ADPr and non-ADPr steadily; however, the number of ADPr spectra 13 
peaked at only 469 (CID CE 40%) when compared to 1,852 for HCD CE 32% on the Lumos (Fig. 2A). 14 
Due to the predominance of p-ions in HCD/CID scans, XCorr values (the cross-correlation score 15 
between a spectrum and the candidate peptide) (23) are typically low for ADPr spectra (Fig. 2B). 16 
Increasing HCD collision energy therefore increases sequential dissociation of, from now on referred to 17 
as, precursor ‘P-ions’ to fragment ‘p-ions’. A concomitant increase in XCorr with increasing HCD collision 18 
energy on the Lumos (Fig. 2B) suggests improved dissociation of the peptide backbone; supplemental 19 
Fig. S4). For example, by comparing an ADPr peptide at two HCD collision energies (Lumos CE 28% vs. 20 
CE 34%), XCorr increases as the p-series score decreases (Fig. 2C,D). The spectrum contains P-ions 21 
at collision energy 28% (Fig. 2C, P1-ion and P5-ion) but those P-ions disappeared or diminished at 22 
collision energy 34% (Fig. 2D), demonstrating that increasing HCD collision energy promotes P-ions to 23 
p-ion (and complementary b- or y-ions) conversion more readily. The dependence on this sequential 24 
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peptide (Fig. 2E). In this case, the intact precursor P5-ion dominates the spectrum that in turn results in 1 
a low XCorr (Fig. 2E). Increasing HCD collision energy on the Q Exactive did not impact the ADPr XCorr 2 
values but did decrease those for non-ADPr spectra likely due to over-fragmentation (Fig. 2B). The 3 
differences in collision energies between these two instruments have been reported (24). The collision 4 
energy offset is -6.7% for the Q Exactive relative to the Lumos (24) which is consistent with our 5 
observations that lower collision energies on the Q Exactive are optimal compared to the Lumos for 6 
identifying ADPr peptides. We present a more detailed analysis of the dependence on collision energy 7 
on the p-series’ dissociation properties further below.  8 
 9 
The M-ion Series Score Provides Qualitative Assessment of Candidate ADPr MS2 Spectra 10 
The ADPr peptides dissociate forming complementary m- and p-ions when using HCD or CID (Fig. 1B). 11 
Although they dominate MS2 spectra, the m-ions (m1, m3, m6 and m8) do not provide any peptide 12 
sequence information, they are nonetheless convenient to run m-ion-triggered MS2 strategies that 13 
increase the specificity of ADPr spectra (11). In this study, we could further exploit the diagnostic m-ions 14 
by using the newly implemented m-series score to evaluate the candidacy of a spectrum to be truly 15 
derived from an ADPr peptide. 16 
Ideally, m-ions would be present only in ADPr spectra, however, co-isolation of ADPr with non-17 
ADPr peptides and potential contamination of nucleic acids (25),  also results in m-ion contamination in 18 
non-ADPr peptide spectra. Irrespective of dissociation method and collision energy, the m-series score 19 
distributions for ADPr spectra are markedly higher and less variable (narrower interquartile ranges) than 20 
those for non-ADPr spectra (Fig. 3A, Rank 1 peptides, 5% FDR). Increasing the HCD collision energy on 21 
the Lumos increases the m-series score, but decreases the m-series score on the Q Exactive (Fig. 3A). 22 
Of note, due to the low mass cut-off in CID MS2 scans (26), the m1-ion is often excluded and thus the 23 
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When considering all HCD collision energy conditions, a minimum m-series score of 30 is 1 
supportive of an ADPr PSM (and a score of 10 for CID spectra, Fig. 3A). Looking closer at the m-series 2 
distribution for one method (Lumos HCD, 28% CE), the difference in m-series score distribution across 3 
spectral classes is particularly pronounced.  The m-series score for ADPr spectra peaks at 40 with the 4 
majority of ADPr PSMs populating the 30 to 60 score range; and the m-series score for non-ADPr spectra 5 
peaks at 5, tailing to the higher scores (Fig. 3B). On the other hand, unidentified spectra exhibit two peaks, 6 
consistent with a mixture of unrecognized non-ADPr and ADPr MS2 events (Fig. 3C). We also compared 7 
the precursor mass [MH+] distributions across the spectral classes and noted that unidentified spectra 8 
with m-series scores ≥30 have a mass distribution similar to that of ADPr spectra (Fig. 3D), reflective of 9 
a higher mass incurred by the ADPr modification (+541 Da). As we noted previously (11), identification 10 
of ADPr PSMs is contingent upon low isolation interference (the percentage of interference by co-isolation 11 
within the precursor isolation window, or, the relative amount of ion current within the isolation window 12 
that is not attributed to the isolated precursor) when compared to their non-ADPr counterparts (Fig. 3E). 13 
These observations emphasize that if solely reliant on standard annotation workflows, ADPr spectra must 14 
be relatively interference-free to be identified with confidence.  This limitation indicates that we are 15 
underreporting the true number of ADPr peptides. The m-series score can therefore be used as a 16 
diagnostic for ADPr spectral candidacy, whose spectrum is then subsequently verified the p-series 17 
annotation (below).   18 
 19 
The M-ion Score Can Be Used to Further Enrich ADPr PSMs at the Spectral Processing Steps 20 
Unidentified spectra comprise ADP peptides (Fig. 3C) that were not annotated for one or more reasons, 21 
including too few b/y-ions due to under or over-fragmentation of the peptide backbone, as confirmed by 22 
our manual inspection of these spectra. We also observed that some of these spectra harbored high 23 
intensity fragment ions indicating that they likely comprise variables not considered in our default search. 24 
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score ≥30 (n=2,875) and re-processed them using semi-trypsin as a search parameter (Experimental 1 
Section, Fig. 3F). We retrieved an additional 34 annotated ADPr PSMs (Rank 1, 5% FDR) and 30 non-2 
ADPr PSMs, with the rest remaining as unidentified (Fig. 3F). An example semi-tryptic ADPr spectrum is 3 
fully annotated when considering both b/y-ions (XCorr = 1.02) and fragment p-ions (p-series score = 4 
1,860) (Fig. 3G).  5 
 6 
ADPr Peptides’ Dissociation Dynamics Differ Across Acquisition Methods  7 
The m-ion series score changes with increasing HCD collision energy (Fig. 3A) implying that the 8 
complementary P-ion and p-ion intensities are also changing, which in turn could impact the dependence 9 
on the p-series score to validate ADPr peptide spectra. We thus examined the individual m-ion intensities 10 
generated by increasing HCD collision energy on the Lumos and Q Exactive with the aim to monitor the 11 
trends of their complementary P-ions.  12 
Firstly, we noted the following striking features of the m-ion series:  the m1- and m6-ion signals 13 
dominate the m-series score; and the m1-ion intensity increases whereas the m6-ion intensity decreases 14 
with increasing HCD collision energy (supplemental Fig. S5A). In contrast, the predominant m6-ion and 15 
the low abundant m8-ion are relatively stable with increasing CID collision energy (supplemental Fig. 16 
S5A). Secondly, we examined the complementary p-series score distributions by monitoring the total p-17 
series score, and its breakdown into the precursor P-ion and fragment p-ion scores (supplemental Fig. 18 
S5B). We also generated a further breakdown of the P-ion series into the individual P1-ion, P3-ion, P5-19 
ion, P8-ion and P10-ion scores (supplemental Fig. S6), to directly monitor their relationships with their 20 
complementary m-ions.  The p-series and the P-ion scores decrease with increasing HCD collision 21 
energy for both the Lumos and Q Exactive but remain stable with CID (supplemental Fig. S5B). 22 
Specifically, the P5-ion dominates HCD and CID MS2 spectra, but there is a shift towards the P1-ion 23 
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The p-ion scores, on the other hand, exhibit diverse trends across the three collision energy 1 
conditions - they remain stable with HCD on the Lumos, decreasing with HCD on the Q Exactive, and 2 
increasing slightly with CID on the Lumos (supplemental Fig. S5B). The differences in the p-ion score 3 
distributions indicate that depending on the instrument platform and collision energy, the reliance on p-4 
ion series annotations to validate ADPr MS2 spectra will vary. For instance, in order to leverage both 5 
XCorr and the p-ion scores, HCD on the Lumos can be performed at collision energies ≥26%, and from 6 
20% to 26% on the Q Exactive (supplemental Fig. S5C). Although CID is not routinely used for ADP-7 
ribosylation studies, higher collision energies promote both increased XCorr and overall p-series scores 8 
(supplemental Fig. S5C).  9 
 10 
The ADPr m1-ion Forms Primarily from the Dissociation of the Larger m-ions 11 
An additional observation from monitoring the formation of m-ions and p-ions over collision energies is 12 
that the predominant m1-ion and lower abundant m3-ion in HCD data are formed due to continued 13 
dissociation of the m6- and m8-ions (supplemental Fig. S5D), rather than solely due to the direct 14 
dissociation of the ADPr peptide to form the m1/P10-ion or m3/P8-ion pairs. For instance, CID spectra 15 
maintain stable m6-ion and m8-ion signals with increasing collision energy, without any notable increase 16 
in the m3-ion signal (the m1-ion cannot be readily captured due to the low mass cut-off rule) 17 
(supplemental Fig. S5D). Direct infusion of AMP (m6-ion) demonstrates this m6- to m1-ion conversion 18 
rather handedly (supplemental Fig. S5E).  In addition, the m1-ion score increases even though higher 19 
collision energies do not increase the prevalence of the complementary P10-ion (Fig. 4A). On the other 20 
hand, the m6-ion score decreases as its complementary P5-ion decreases with increasing collision 21 
energy (Fig. 4B). Moreover, we cannot rule out that the m10-ion (intact ADPr moiety), although very low 22 
in abundance in HCD scans and not considered in the m-series score, is a source of the lower mass m-23 
ions. We noted that in CID spectra, the m10-ion is more readily detected (Fig. 4C), compared to the 24 
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4E). We therefore interpret these data to indicate that with HCD, once the complete ADPr modification is 1 
lost, it continues to dissociate, and contributing to one or more of the lower mass m-ions (Fig. 4F). Taken 2 
together all observations to this point, for the majority of ADPr peptide spectra, validation via the p-series 3 
score will most likely be dependent on the precursor/fragment P1-/p1-, P3-/p3- and P5-/p5-ions. In 4 
addition, the p3- and p5-ions (and p8- and p10-ions if observed) will facilitate amino acid localization 5 
since they retain part of the ADPr moiety. 6 
 7 
P-series Score Facilitates Inclusion of Low Scoring Spectra as ADP-ribosylated   8 
The final evaluation of the ADPr peptide annotation workflow using the pilot liver data was to determine 9 
whether the p-series score could be used to systematically evaluate and increase the number of 10 
reportable ADPr peptides. Candidate ADPr peptide spectra may rely on one or both p-series ions for 11 
validation; however, lower scoring spectra supported by p-ions are more beneficial since they provide 12 
peptide sequence information and the potential to localize the amino acid acceptor site. We examined 13 
more closely the HCD (ie., 28% CE) data from the Lumos and noted that as the ADPr peptides’ charge 14 
states increase, the higher the p-series score cut-off required to include lower XCorr spectra (cut-off 15 
based on the Fixed PSM Score in Proteome Discoverer) (Fig. 5A-C, supplemental Fig. S7A). For example, 16 
precursor charges 2+ and 3+ benefit from a p-series score cut-off of 10 (Fig. 5A, B), but higher charge 17 
states ≥4+ that comprise larger peptides (supplemental Fig. S7B) require a more stringent cut-off of 100 18 
(Fig. 5C). Example lower XCorr spectra from protein disulfide-isomerase (P4HB), mitochondrial fission 19 
regulator 1 (MTFR1), and phosphoglucomutase (PGM1) demonstrate that the p-ions corroborate the 20 
sequence identification (Fig. 5D-F).  21 
 22 
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We established an in vivo model for acute proinflammatory responses using an intraperitoneal injection 1 
of IFN-. Each organ contains cells that are known responders to IFN-: the spleen is a reservoir for 2 
monocytes and other immune cells (27) and the human liver cell line, HepG2, is known to exhibit a typical 3 
IFN- response (28). Moreover, PARP14 mRNA is highly expressed in human spleen as documented on 4 
proteinatlas.org (supplemental Fig. S8A).  5 
 We confirmed that the liver and spleen organs were responsive to IFN- as gauged by the 6 
increase in mRNA levels of IFN--inducible chemokines (e.g., Ccl2), and Parp14 and Parp9 (11, 18) 7 
(supplemental Fig. S8B, C).  On the other hand, Parp1 mRNA tended to decrease but this decrease was 8 
not significant (supplemental Fig. S8B, C). Before analyzing IFN--induced changes to each organ we 9 
combined ADPr peptide data from each condition, control, saline and IFN-, and compared the ADPr 10 
peptide and protein profiles between liver and spleen (supplemental Tables S2 and S3). EThcD and HCD 11 
ADPr peptide identifications overlap well, 72% and 59% for liver and spleen, respectively (Fig. 6A). These 12 
ADPr peptides corresponded to 429 liver and 95 spleen proteins of which 50 (11%) overlapped (Fig. 6A). 13 
In contrast, the overlap of common proteins detected in the liver and spleen proteomes is 43.3% (Fig. 14 
6B), most likely due to the equal depth in proteome sequencing in the latter. With a relatively limited 15 
number of spleen ADPr proteins compared to those from liver, inter-organ comparisons are not 16 
informative. The majority of ADPr proteins were identified in each organ’s proteome whereas 92 and 22 17 
ADPr proteins were not accounted for in the liver and spleen proteomes, respectively (Fig. 6B, 18 
supplemental Table S4). In addition, we gained 25% (liver) and 17% (spleen) additional ADPr proteins 19 
by implementing the p-series annotation and score (Fig. 6C).  20 
Liver-unique ADPr proteins (from Fig. 6A) form networks related to SRP-dependent 21 
cotranslational protein targeting to membrane (green cluster), protein folding and lipoprotein assembly 22 
(gold cluster), metabolism and catabolism (light blue and olive-green clusters), and respiratory electron 23 
transport chain function (purple cluster) (Fig. 6D). However, spleen-unique ADPr proteins (from Fig. 6A)  24 
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cluster), and regulation of action potential (blue cluster) (Fig. 6E). ADPr proteins common to liver and 1 
spleen are primarily related to protein translation (Fig. 6F).   2 
 3 
Mouse Liver and Spleen Respond Differently to Systemic IFN-  4 
Spleen and liver proteomes exhibited contrasting responses to IFN-. A markedly large proportion of the 5 
spleen proteome decreased (28%) whereas only 2% increased in abundance (Fig. 7A). Liver on the other 6 
hand exhibited a more balanced response with a 4% increase and 1% decrease in the quantified 7 
proteome in response to IFN- (Fig. 7A). The Mouse Gene Atlas database analysis of these proteins 8 
indeed recognized blood and immune cell types within the top five outputs for decreased spleen proteins 9 
(mega erythrocyte progenitor, follicular B-cells and macrophages) (Fig. 7B). On the other hand, while 10 
macrophages were indicated in both increased and decreased liver proteins, the term was supported by 11 
fewer protein overlaps compared with spleen (Fig. 7B). Proteins that increased in liver and decreased in 12 
spleen were also associated with adipose tissues (Fig. 7B); primarily due to metabolic term such as fatty 13 
acid biosynthesis, owing to enzymes such as acetyl-CoA carboxylase 2 (ACAB2 in liver), and medium-14 
chain specific acyl-CoA dehydrogenase and small-chain specific acyl-CoA dehydrogenase (ACADM and 15 
ACADS, respectively in spleen).  16 
Cytokine responsive genes whose proteins increased in the liver, included ‘signal transducer and 17 
activator of transcription’ members STAT1 and STAT3, and ‘interferon gamma-induced GTPase’ IGTB 18 
(supplemental Table S5). In the spleen on the other hand, STAT2, STAT3 and STAT5a were all 19 
decreased (supplemental Table S6).  Of note, we detected PARP enzymes only in the spleen. PARP1 20 
and PARP3 decreased whereas PARP9 increased in response to IFN-(supplemental Table S6), 21 
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Changing ADPr Peptides Represent a Complex Tissue Response to IFN-  1 
ADP-ribosylation, based on Western blot analysis, demonstrated that the net ADP-ribosylation signal 2 
in liver, although variable, remained relatively stable up to 8-hours post-IFN- injection when compared 3 
to the dramatic decrease in spleen (supplemental Fig. S9). These observations, in addition to the 4 
decrease in the proteome (Fig. 7A), suggest that immune cells likely vacated the spleen and entered 5 
circulation in response to IFN-(29). Rather interestingly, the overall changes to the ADPr peptides from 6 
liver and spleen, do not reflect the anti-ADPr Western blot analysis. Using a two-group comparison (saline 7 
versus IFN-; p<0.05; q=0.62 liver, q=0.23 spleen), the majority of liver ADPr peptides decreased, 8 
whereas the numbers of increased and decreased spleen ADPr peptides were similar (Fig. 7C).  In 9 
particular, several spleen ADPr peptides that increased are from hemoglobins HBA and HBB, however 10 
these proteins’ abundances also increased (supplemental Table S7). We therefore cannot discern 11 
whether the increases in these ADPr signatures are due to an increase in the baseline protein or to an 12 
increase in ADPr status itself. On the other hand, most proteins corresponding to altered liver ADPr 13 
peptides (increased or decreased) did not change in response to IFN- (supplemental Table S8). 14 
Specifically, two ‘fatty acid binding protein 1’ FABP1 ADPr peptides increased whereas FABP1 itself 15 
remained unchanged with IFN-(Fig. 7C, supplemental Table S8).  16 
 17 
The P-ion Series Can Facilitate Amino Acid Acceptor Site Validation 18 
HCD scans provided us more ADPr peptide identifications when compared to EThcD (Fig. 6A), but EThcD 19 
is superior for amino acid acceptor site localization (11, 20). In particular, we described a PARP14 ADPr 20 
peptide (HISGLAQALSK) as decreasing in the spleen IFN- treated group (Fig. 7C). This peptide was 21 
originally identified only by HCD and was annotated by the search engine as being modified at the n-22 
terminal histidine (Fig. 7D). The presence of unmodified y-ions immediately downstream of the histidine 23 
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the understanding that p1-ions are indistinguishable from unmodified fragment ions we performed 1 
targeted MS2 (tMS2) with EThcD (HCD CE 22.5%). tMS2 confirmed our notion that a downstream amino 2 
acid, in this case the serine-3, is the correct acceptor site, as supported by the targeted EThcD analysis 3 
(Fig. 7D, supplemental Fig. 10B). Moreover, tMS2 at HCD collision energy 20%, although not ideal for 4 
backbone fragmentation, provided support for the serine-3 by the preservation of the y10+ p3-ion (Fig. 5 
7D, supplemental Fig. 10C). In a second example, we examined more closely the changing liver FABP1 6 
ADPr peptide (GVSEIVHEGKK that increased with IFN-) whose search engine rank1 assigned the c-7 
terminal lysine as ADP-ribosylated (Fig. 7E, supplemental Fig. 11A). Again, the assignment was 8 
supported by the presence of the presumed b10-ion that instead, is annotated as a p1-ion, along with the 9 
definitive p3-ion, when the lysine-10 is assigned as ADP-ribosylated for the rank2 peptide (Fig. 7E, 10 
supplemental Fig. 11B). The parallel EThcD scan (same precursor ion) also supports the ADPr 11 
assignment to the lysine-10 (Fig. 7E, supplemental Fig. 11C).  12 
Despite these specific examples we have not yet explored methods that can evaluate acceptor 13 
sites using the p-series at a wide-scale level. We therefore relied on available EThcD scans whose amino 14 
acid assignment probabilities were ≥95% to summarize the acceptor site trends. When considering the 15 
combined data for all three treatment groups (control, saline, INF-) for each organ (see Experimental 16 
Section), the predominant acceptor site is lysine for both spleen and liver (Fig. 7F). Although we 17 
sequenced far fewer ADPr peptides in the spleen, serine and histidine are the second most abundant 18 
acceptor sites, whereas all other acceptor sites are more evenly distributed for the liver (Fig. 7F).  19 
 20 
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Discussion 1 
ADP-ribosylome studies are increasing but those that are reliant on HCD face numerous challenges. The 2 
ADPr moiety is unstable and inconsistently so depending on collision energy and instrument platform as 3 
we have demonstrated; and depending on the amino acceptor site (15, 30). The resulting fragment 4 
spectra therefore contain signals owing to backbone b/y ions, and neutral or modifications loss ions 5 
(resulting in the precursor ‘P-ions’), but also to dissociation of both the peptide and ADPr bonds (fragment 6 
‘p-ions’) that are not considered during annotation. Due to the prevalence of P-ions and p-ions at the cost 7 
of HCD-generate b/y-ions, ADPr peptide spectral scores (ie., XCorr) are lower than those of unmodified 8 
peptides and are less likely to pass spectral quality criteria.  ETD-dependent strategies provide one 9 
solution to ADPr lability since they shift fragmentation to favor the peptide backbone’s dissociation (17); 10 
however, HCD-dependent peptide sequencing is more widely used thus computational strategies that 11 
can address spectral quality are warranted. We therefore implemented an ADPr peptide annotation 12 
module that is inserted post-spectral searching and scoring. This node provides measures of ADPr 13 
peptide spectral candidacy, based on the m-ion series score, and ADPr peptide validation based on the 14 
p-series score; with the latter supporting lowering spectral score thresholds, thereby increasing the 15 
number of reportable ADPr peptides and proteins. 16 
Before investigating the effects of IFN- infusion on mice spleen and liver, we used a pilot study’s 17 
liver ADPr peptide samples to perform collision energy experiments that demonstrated the following ADPr 18 
peptide fragmentation properties observed on the Lumos and Q Exactive: 1) The P5-, P3- and P1-ions 19 
are the predominant P-ions; but only the corresponding m6-ion, and not the m8- and m10-ions, 20 
respectively, prevail in HCD scans. 2) The m1-ion, although prevalent in HCD spectra, is formed primarily 21 
from the dissociation of the larger m-ions, with some contributions from the formation of the 22 
complementary P10-ion. 3) When considering the m1-, m3-, m6- and m8-ions, an m-series score ≥30 is 23 
diagnostic of a spectrum containing an ADPr modification for spectra solely dependent on HCD; provided 24 
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dissociate into p-ions with increasing collision energy (supplemental Fig. S5). 5) The p-series score 1 
distribution varies markedly with instrument platform and collision energy. 6) The p-series score can be 2 
used to justify inclusion of lower confidence ADPr peptides. 7) The m-series and p-series scores are 3 
useful metrics to evaluate further the properties of HCD-generated ADPr peptide spectra.  4 
Since the m-ions are diagnostic for the presence of an ADPr moiety itself, and are not unique to 5 
the peptide itself, the m-series score can be calculated for all MS2 spectra. The annotation of P-ions and 6 
p-ions, and calculation of the p-series score, however, is contingent upon the search algorithm rendering 7 
a spectrum an ADPr peptide candidate. Unannotated MS2 spectra that may be plentiful with ADPr 8 
peptides, can be thus be inferred from the m-series scores. This systematic annotation and scoring of 9 
the m-ion and p-ion series ions will therefore facilitate studies aiming to characterize basal levels or mild 10 
stimulants such as IFN- induction of PARP enzyme activities, whose ADPr peptide yields are less than 11 
those recovered from the potent stimulant H2O2 (17).  12 
In this study, we confirmed that liver and spleen responded to IFN- injection by the increase in mRNA 13 
of prototypical IFN--responsive genes including Parp14 and Parp9. Quantitative analysis of the 14 
proteomes indicated that the spleen was more responsive, based on the marked reduction of proteins in 15 
the IFN- group.  The dramatic decrease in the spleen proteome may be due to a mass release of 16 
monocytes that are known to vacate the subcapsular red cap in response to acutely or chronically 17 
damaged tissues such as an infarcted myocardium or atherosclerotic plaques, respectively (27, 29, 31). 18 
On the other hand, there still remains resident macrophages and dendritic cells in the marginal zone (29) 19 
that could have contributed to the increase in mRNA of the IFN-responsive genes. The liver’s response 20 
on the other hand, was more balanced for increasing and decreasing proteins. The liver comprises 21 
several cell types including hepatocytes, Kupffer cells, sinusoidal endothelial cells and fat storing cells 22 
(32), any of which could have responded to IFN-, but unlike the spleen do not evacuate the organ upon 23 









Enhanced annotation of ADP-ribosylated peptide spectra 
31 
The observed changes to the liver and spleen ADP-ribosylomes are more challenging to interpret. 1 
The anti-ADP-ribosylation Western analysis indicated a dramatic decrease in spleen ADPr signal up to 2 
eight hours post-IFN-; whereas that from liver was variable over the same time course, yet relatively 3 
stable when compared to the spleen’s response. On the other hand, quantitative analysis of the ADPr 4 
peptides resulted in a net increase in ADPr peptide signal in liver, and a balance in the increasing and 5 
decreasing responses in spleen. The differences between Western blot and quantitative ADPr peptide 6 
analysis are not contradictory per se but emphasize that the former is too vague and the latter too specific 7 
a descriptor of ADPr signaling events. For instance, a decrease in an ADPr peptide’s abundance can be 8 
due to a removal of the ADPr modification itself, but also to a net decrease in the total protein abundance, 9 
a hyper-ADP-ribosylation event on the surrounding amino acids, or the addition of another 10 
posttranslational modification. Thus, a loss in a modified peptide’s abundance is not exclusive to a 11 
reduction in the PTM’s occupancy (33); and vice versa, an increase could result as a result of the opposite 12 
events described above. Moreover, the complexity of cell types comprising each organ makes it difficult 13 
to determine the cellular source(s) of the final ADPr signatures. As ADP-ribosylome workflows improve 14 
however (17), there will be lesser reliance on milligrams protein inputs to enrich ADPr peptides. Studies 15 
aiming to sort cells from complex tissues that in turn reduce protein yields will inevitably be possible, in a 16 
manner similar to the evolution of phosphoproteomics workflows (34). 17 
We previously studied the IFN- induced proteome and ADP-ribosylome changes to the human 18 
macrophage-like cell line, THP-1 (11), that when compared to the in vivo experiments yielded more 19 
consistent ADP ribosylation trends. In THP-1 cells, the anti-ADP-ribosylation Western signal increased 20 
steadily up to 12 hours and the corresponding changes to ADPr peptides also skewed towards increased 21 
ADPr peptide abundances (11). Proteins whose ADP-ribosylation statuses increased in THP-1 cells 22 
included PARP9 and PARP14, and several ribosomal subunits associated with SRP-dependent protein 23 
translation; whereas those that decreased were relatively few, including PARP1 (8, 11).  In particular, we 24 
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independent of the increase in the protein abundances (11). In this current study, we identified a distinct 1 
spleen PARP14 ADPr peptide that decreased in response to IFN-. Although we did not detect PARP14 2 
in the proteome, we expect that the increase in its mRNA supports an increase in PARP14 protein, since 3 
PARP9 protein was detected and increased in IFN-.  4 
Despite the identification of multiple ADPr sites on PARP14 described previously (10, 11, 17), the 5 
functional roles of these ADPr sites are not known. The PARP14 ADPr peptide identified in spleen 6 
(840_HIS(ADPr)GLAQALSK_850), however, underscores the challenges associated with HCD-7 
dependent acceptor site mapping of posttranslational modifications (15, 30). If solely dependent on HCD, 8 
the n-terminal histidine would have been assigned as the acceptor site, but EThcD confirmed the 9 
downstream serine to be the true acceptor site. Moreover, as guided by the observations that a lower 10 
collision energy on the Lumos shifts away from complete loss of the ADPr (p1-ion) and towards p-ions 11 
retaining residual ADPr (ie. p3-ion in Fig. 7D, supplemental Fig. S6), we could demonstrate the serine to 12 
be the correct acceptor with HCD. Similarly, the p5-ion for FABP2 ADPr peptide supported the search 13 
engine rank2 (lysine-10) assignment over the rank1 (lysine-11) (Fig. 7E), underscoring the practicality of 14 
employing the p-ion series annotation. It is also imperative to note that for each case, we detected only 15 
a single chromatographic peak for each PARP14 and FABP1 ADPr peptide, indicating that our analysis 16 
was not complicated by overlapping ADPr peptide forms.  17 
In summary, our study presents initial and critical steps towards advancing ADPr peptide spectral 18 
annotation.  The workflow improves HCD-generated ADPr peptide confidence by incorporating the p-ion 19 
series annotations and scores. As interestingly, both m-ion and p-ion series scores can guide researchers 20 
through alternative mass spectrometric acquisition methods and data processing strategies, that in turn 21 
improve sequencing depth, with the potential to increase the breadth of biological findings.  22 









Enhanced annotation of ADP-ribosylated peptide spectra 
33 
Data Availability 1 
The mass spectrometry and resulting search data have been deposited to the ProteomeXchange 2 
Consortium via the PRIDE (35) partner repository with the dataset identifier PXD027454 and 3 
10.6019/PXD027454, username: reviewer_pxd027454@ebi.ac.uk and password: Svdx1p3G. 4 
 5 
Conflict of Interest 6 
This study was in part supported by research grants to Masanori Aikawa from Kowa Company, Ltd. 7 
Nagoya, Japan, and the National Heart Lung and Blood Institute (R01HL126901 and R01HL149302). 8 













1. Kraus, W. L. (2020) PARPs and ADP-ribosylation: 60 years on. Genes Dev 3 
2. Hendriks, I. A., Larsen, S. C., and Nielsen, M. L. (2019) An Advanced Strategy for 4 
Comprehensive Profiling of ADP-ribosylation Sites Using Mass Spectrometry-based Proteomics. Mol 5 
Cell Proteomics 18, 1010-1026 6 
3. Leslie Pedrioli, D. M., Leutert, M., Bilan, V., Nowak, K., Gunasekera, K., Ferrari, E., Imhof, R., 7 
Malmstrom, L., and Hottiger, M. O. (2018) Comprehensive ADP-ribosylome analysis identifies tyrosine 8 
as an ADP-ribose acceptor site. EMBO Rep 19 9 
4. Leidecker, O., Bonfiglio, J. J., Colby, T., Zhang, Q., Atanassov, I., Zaja, R., Palazzo, L., 10 
Stockum, A., Ahel, I., and Matic, I. (2016) Serine is a new target residue for endogenous ADP-11 
ribosylation on histones. Nat Chem Biol 12, 998-1000 12 
5. Yan, F., Huang, C., Wang, X., Tan, J., Cheng, S., Wan, M., Wang, Z., Wang, S., Luo, S., Li, A., 13 
Guo, X., Feng, M., Liu, X., Zhu, Y., and Zhou, Y. (2020) Threonine ADP-Ribosylation of Ubiquitin by a 14 
Bacterial Effector Family Blocks Host Ubiquitination. Mol Cell 78, 641-652 e649 15 
6. Hassa, P. O., Haenni, S. S., Elser, M., and Hottiger, M. O. (2006) Nuclear ADP-ribosylation 16 
reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev 70, 17 
789-829 18 
7. Kim, D. S., Challa, S., Jones, A., and Kraus, W. L. (2020) PARPs and ADP-ribosylation in RNA 19 
biology: from RNA expression and processing to protein translation and proteostasis. Genes Dev 34, 20 
302-320 21 
8. Fehr, A. R., Singh, S. A., Kerr, C. M., Mukai, S., Higashi, H., and Aikawa, M. (2020) The impact 22 
of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions. Genes Dev 34, 341-23 
359 24 
9. Nishizuka, Y., Ueda, K., Honjo, T., and Hayaishi, O. (1968) Enzymic adenosine diphosphate 25 
ribosylation of histone and poly adenosine diphosphate ribose synthesis in rat liver nuclei. J Biol Chem 26 
243, 3765-3767 27 
10. Larsen, S. C., Leutert, M., Bilan, V., Martello, R., Jungmichel, S., Young, C., Hottiger, M. O., and 28 
Nielsen, M. L. (2017) Proteome-Wide Identification of In Vivo ADP-Ribose Acceptor Sites by Liquid 29 
Chromatography-Tandem Mass Spectrometry. Methods Mol Biol 1608, 149-162 30 
11. Higashi, H., Maejima, T., Lee, L. H., Yamazaki, Y., Hottiger, M. O., Singh, S. A., and Aikawa, M. 31 
(2019) A Study into the ADP-Ribosylome of IFN-gamma-Stimulated THP-1 Human Macrophage-like 32 
Cells Identifies ARTD8/PARP14 and ARTD9/PARP9 ADP-Ribosylation. J Proteome Res 18, 1607-1622 33 
12. Daniels, C. M., Ong, S. E., and Leung, A. K. L. (2017) ADP-Ribosylated Peptide Enrichment 34 
and Site Identification: The Phosphodiesterase-Based Method. Methods Mol Biol 1608, 79-93 35 
13. Hengel, S. M., Shaffer, S. A., Nunn, B. L., and Goodlett, D. R. (2009) Tandem mass 36 









Enhanced annotation of ADP-ribosylated peptide spectra 
35 
14. Rosenthal, F., Nanni, P., Barkow-Oesterreicher, S., and Hottiger, M. O. (2015) Optimization of 1 
LTQ-Orbitrap Mass Spectrometer Parameters for the Identification of ADP-Ribosylation Sites. J 2 
Proteome Res 14, 4072-4079 3 
15. Gehrig, P. M., Nowak, K., Panse, C., Leutert, M., Grossmann, J., Schlapbach, R., and Hottiger, 4 
M. O. (2020) Gas-Phase Fragmentation of ADP-Ribosylated Peptides: Arginine-Specific Side-Chain 5 
Losses and Their Implication in Database Searches. J Am Soc Mass Spectrom 6 
16. Zee, B. M., and Garcia, B. A. (2010) Electron transfer dissociation facilitates sequencing of 7 
adenosine diphosphate-ribosylated peptides. Anal Chem 82, 28-31 8 
17. Buch-Larsen, S. C., Hendriks, I. A., Lodge, J. M., Rykaer, M., Furtwangler, B., Shishkova, E., 9 
Westphall, M. S., Coon, J. J., and Nielsen, M. L. (2020) Mapping Physiological ADP-Ribosylation Using 10 
Activated Ion Electron Transfer Dissociation. Cell Rep 32, 108176 11 
18. Iwata, H., Goettsch, C., Sharma, A., Ricchiuto, P., Goh, W. W., Halu, A., Yamada, I., Yoshida, 12 
H., Hara, T., Wei, M., Inoue, N., Fukuda, D., Mojcher, A., Mattson, P. C., Barabasi, A. L., Boothby, M., 13 
Aikawa, E., Singh, S. A., and Aikawa, M. (2016) PARP9 and PARP14 cross-regulate macrophage 14 
activation via STAT1 ADP-ribosylation. Nat Commun 7, 12849 15 
19. Nowak, K., Rosenthal, F., Karlberg, T., Butepage, M., Thorsell, A. G., Dreier, B., Grossmann, J., 16 
Sobek, J., Imhof, R., Luscher, B., Schuler, H., Pluckthun, A., Leslie Pedrioli, D. M., and Hottiger, M. O. 17 
(2020) Engineering Af1521 improves ADP-ribose binding and identification of ADP-ribosylated proteins. 18 
Nat Commun 11, 5199 19 
20. Bilan, V., Leutert, M., Nanni, P., Panse, C., and Hottiger, M. O. (2017) Combining Higher-20 
Energy Collision Dissociation and Electron-Transfer/Higher-Energy Collision Dissociation 21 
Fragmentation in a Product-Dependent Manner Confidently Assigns Proteomewide ADP-Ribose 22 
Acceptor Sites. Anal Chem 89, 1523-1530 23 
21. Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., 24 
Doncheva, N. T., Morris, J. H., Bork, P., Jensen, L. J., and Mering, C. V. (2019) STRING v11: protein-25 
protein association networks with increased coverage, supporting functional discovery in genome-wide 26 
experimental datasets. Nucleic Acids Res 47, D607-D613 27 
22. Kuleshov, M. V., Jones, M. R., Rouillard, A. D., Fernandez, N. F., Duan, Q., Wang, Z., Koplev, 28 
S., Jenkins, S. L., Jagodnik, K. M., Lachmann, A., McDermott, M. G., Monteiro, C. D., Gundersen, G. 29 
W., and Ma'ayan, A. (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 30 
update. Nucleic Acids Res 44, W90-97 31 
23. Eng, J. K., McCormack, A. L., and Yates, J. R. (1994) An approach to correlate tandem mass 32 
spectral data of peptides with amino acid sequences in a protein database. J Am Soc Mass Spectrom 33 
5, 976-989 34 
24. Zolg, D. P., Wilhelm, M., Yu, P., Knaute, T., Zerweck, J., Wenschuh, H., Reimer, U., 35 
Schnatbaum, K., and Kuster, B. (2017) PROCAL: A Set of 40 Peptide Standards for Retention Time 36 
Indexing, Column Performance Monitoring, and Collision Energy Calibration. Proteomics 17 37 
25. Potel, C. M., Lin, M. H., Heck, A. J. R., and Lemeer, S. (2018) Defeating Major Contaminants in 38 
Fe(3+)- Immobilized Metal Ion Affinity Chromatography (IMAC) Phosphopeptide Enrichment. Mol Cell 39 









Enhanced annotation of ADP-ribosylated peptide spectra 
36 
26. Wu, W. W., Wang, G., Insel, P. A., Hsiao, C. T., Zou, S., Maudsley, S., Martin, B., and Shen, R. 1 
F. (2011) Identification of proteins and phosphoproteins using pulsed Q collision induced dissociation 2 
(PQD). J Am Soc Mass Spectrom 22, 1753-1762 3 
27. Potteaux, S., Ait-Oufella, H., and Mallat, Z. (2015) Role of splenic monocytes in atherosclerosis. 4 
Curr Opin Lipidol 26, 457-463 5 
28. Melen, K., Keskinen, P., Lehtonen, A., and Julkunen, I. (2000) Interferon-induced gene 6 
expression and signaling in human hepatoma cell lines. J Hepatol 33, 764-772 7 
29. Swirski, F. K., Nahrendorf, M., Etzrodt, M., Wildgruber, M., Cortez-Retamozo, V., Panizzi, P., 8 
Figueiredo, J. L., Kohler, R. H., Chudnovskiy, A., Waterman, P., Aikawa, E., Mempel, T. R., Libby, P., 9 
Weissleder, R., and Pittet, M. J. (2009) Identification of splenic reservoir monocytes and their 10 
deployment to inflammatory sites. Science 325, 612-616 11 
30. Bonfiglio, J. J., Colby, T., and Matic, I. (2017) Mass spectrometry for serine ADP-ribosylation? 12 
Think o-glycosylation! Nucleic Acids Res 45, 6259-6264 13 
31. Nahrendorf, M., Swirski, F. K., Aikawa, E., Stangenberg, L., Wurdinger, T., Figueiredo, J. L., 14 
Libby, P., Weissleder, R., and Pittet, M. J. (2007) The healing myocardium sequentially mobilizes two 15 
monocyte subsets with divergent and complementary functions. J Exp Med 204, 3037-3047 16 
32. Baratta, J. L., Ngo, A., Lopez, B., Kasabwalla, N., Longmuir, K. J., and Robertson, R. T. (2009) 17 
Cellular organization of normal mouse liver: a histological, quantitative immunocytochemical, and fine 18 
structural analysis. Histochem Cell Biol 131, 713-726 19 
33. Singh, S. A., Winter, D., Bilimoria, P. M., Bonni, A., Steen, H., and Steen, J. A. (2012) 20 
FLEXIQinase, a mass spectrometry-based assay, to unveil multikinase mechanisms. Nat Methods 9, 21 
504-508 22 
34. Humphrey, S. J., Karayel, O., James, D. E., and Mann, M. (2018) High-throughput and high-23 
sensitivity phosphoproteomics with the EasyPhos platform. Nat Protoc 13, 1897-1916 24 
35. Perez-Riverol, Y., Csordas, A., Bai, J., Bernal-Llinares, M., Hewapathirana, S., Kundu, D. J., 25 
Inuganti, A., Griss, J., Mayer, G., Eisenacher, M., Perez, E., Uszkoreit, J., Pfeuffer, J., Sachsenberg, T., 26 
Yilmaz, S., Tiwary, S., Cox, J., Audain, E., Walzer, M., Jarnuczak, A. F., Ternent, T., Brazma, A., and 27 
Vizcaino, J. A. (2019) The PRIDE database and related tools and resources in 2019: improving support 28 
for quantification data. Nucleic Acids Res 47, D442-D450 29 
 30 









Enhanced annotation of ADP-ribosylated peptide spectra 
37 
LIST OF FIGURES 1 
FIG. 1. ADP-ribosylome bench to spectral annotation workflow. A, IFN- induced ADP-ribosylome 2 
study. 10-week old sibling mice were injected with saline or IFN-, or nothing at all (no treatment control) 3 
(n=6 per treatment group). Spleen and liver organs were harvested for subsequent mono-ADPr 4 
(MAR)ylated peptide enrichment. The samples were analyzed by the Q Exactive and/or the Lumos and 5 
the spectra were annotated using SEQUEST via Proteome Discoverer 2.4. B, The ADPr structure and 6 
fragment ions (modification ion, m-ion (and [MH]+ values); the complementary peptide ion, p-ion). Amino 7 
acid acceptor sites are indicated. C, Schematic of a typical HCD-generated ADPr peptide spectrum. D, 8 
Candidate ADPr spectra identified and scored (XCorr) by the search engine (SEQUEST-HT) are then 9 
supplemented with m-ion and p-ion series scores to help validate the assignments. 10 
FIG. 2. Distributions of ADPr, non-ADPr and unidentified spectra in collision energy experiments. 11 
A, The impact of varying instrument platform, dissociation method and collision energy on the number of 12 
annotated ADPr spectra vs. non-ADPr and unidentified spectra (individual numbers are labeled within 13 
each bar). The average collision energy percentages are plotted to the right. Annotated spectra include 14 
only rank1 peptides (5% FDR). B, The relationship between XCorr and collision energy (ColE) for ADPr 15 
and non-ADPr peptides. C-E, An ADPr peptide from mouse liver Selenium-binding protein 1/2 16 
(SELENBP1/2) sequenced by HCD CE 28% (C) or CE 34% (D) and CID CE 40% (E) on the Lumos. The 17 
purple arrows highlight precursor P-ions that tend to predominate at lower HCD collision energies (eg. 18 
CE 28%) or in CID spectra; but dissociate further as HCD collision energy increases (eg., CE 34%). Fully 19 
annotated spectra are in supplemental Fig. S4. 20 
FIG. 3. ADPr peptide m-ion score distributions. A, The m-ion series score distributions calculated from 21 
the spectra of annotated ADPr and non-ADPr PSMs (Rank 1, 5% FDR). B, A closer analysis of the m-22 
series score distributions comparing Lumos HCD (28% CE)-generated ADPr and non-ADPr PSMs. C, 23 
The m-series score distribution for the corresponding unidentified spectra from panel B. Candidate ADPr 24 









Enhanced annotation of ADP-ribosylated peptide spectra 
38 
([MH]+) across the spectral categories. E, Distribution of percent isolation interference across spectral 1 
categories. F, An example workflow strategy (ie., semi-trypsin search) to further okayannotate ADPr 2 
spectra from the unidentified category. G, Example semi-tryptic ADPr spectrum previously contained 3 
within unidentified (default fully tryptic search) spectral category.  4 
FIG. 4. The m-ions undergo sequential dissociation. A, The m1/P10-ion dynamics with two HCD 5 
collision energy settings on the Lumos. B, The m6/P5-ion dynamics with two HCD collision energy 6 
settings on the Lumos. C and D, An ADPr peptide analyzed by CID (C) or HCD (D) on the Lumos, 7 
demonstrating that the ADPr molecule is more readily detected in CID but not HCD, likely due to 8 
sequential dissociation. E, The P1-ion is prevalent in HCD and CID scans, despite the low signal for the 9 
corresponding m10-ion in HCD data, suggesting the m10-ion dissociates further in HCD. F, A summary 10 
of the dissociation properties of ADPr peptides when using HCD.  11 
FIG. 5. P-series support inclusion of medium confidence ADPr peptide identifications. A-C, P-12 
series vs. XCorr grouped by precursor charge. PSMs are rank 1, 5% FDR. XCorr thresholds (0.8, z=2+; 13 
1.0, z=3+; 1.2, z>3+) are based on the Fixed PSM Scorer’s medium confidence thresholds. The p-series 14 
cut-off was based on manual inspection of several spectra. PSMs inside of gray area will not be 15 
considered further. D-F, Example medium confidence (5% FDR), low XCorr ADPr spectra supported by 16 
p-series ions. P4HB, Protein disulfide-isomerase; MTRF1, Peptide chain release factor 1; PGM1, 17 
Phosphoglucomutase-1. 18 
FIG. 6. The distinct ADP-ribosylomes from mouse liver and spleen. A, Total Rank 1 unique ADPr 19 
peptide sequences identified using HCD and EThcD events triggered from the same precursor scan, and 20 
their corresponding proteins. B, Overlap between liver and spleen proteomes, and liver and spleen ADPr 21 
proteins with their respective proteomes. The proteomes were analyzed with a single HCD acquisition, 22 
whereas the ADP-ribosylomes were analyzed by multiple gas phase separation (GPS) acquisitions. 23 
Proteins from each portion of the Venn diagram are in Supplemental Table S4. C, Total ADPr proteins 24 
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in the database; highest confidence edge strength reported, 0.900. E, STRING database ‘full network’ 1 
output for the spleen unique ADPr proteins: 43/45 proteins in the database; at least medium confidence 2 
edge strength reported, 0.400. F, STRING database ‘full network’ output for the overlapping common 3 
ADPr proteins: 47/50 in the database; at least high confidence edge strength reported, 0.700. For C-E, 4 
disconnected nodes are hidden; and k-means clusters (n=10 for liver; n=3 for spleen; n=2 for common 5 
proteins) were chosen manually after iterations of varying cluster number with subsequent Gene 6 
Ontology analysis. Dashed lines are interactions separated by clusters.  7 
FIG. 7.  IFN- induces distinct responses in mouse liver and spleen. A, Changes to mice spleen and 8 
liver proteomes in response to IFN-. The average of n=3 (spleen pools) and n=6 (liver) for saline versus 9 
IFN-. B, Cell and tissue-specific terms recognized by the Mouse Gene Atlas database for IFN--induced 10 
proteome changes. C, Heat maps of two-group comparisons of changing ADPr peptides (p<0.05; q=0.23 11 
spleen and q=0.62 liver). [Gene name and [amino acid position]. D, p1-ions are assumed to be y-ions by 12 
the search engine. Target MS2 (tMS2) of a candidate His-modified ADPr confirms the downstream Ser 13 
to be the correct site. E, A p1-ion is assumed to be a b-ion by the search engine. The p-series annotation 14 
indicates the lower ranking (rank 2) peptide to be correct; EthcD supports the rank2 assignment. F, 15 
EThcD-based summary of ADPr acceptor sites. Only the GPS scan m/z 400-1500 was used for the 16 
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LIST OF SUPPLEMENTAL FIGURES 1 
Supplemental Figure S1. Removal of GST-tagged-eAf1521 protein from ADPr-peptides using 2 
various commercially available molecular weight cut-off (MWCO) filters. A, The final step for the 3 
prototypical ADPr-peptide enrichment protocol is the trifluoroacetic acid (TFA) release of ADPr-peptides 4 
and eAf1521 from sepharose beads. B, A coomassie blue stain of the ADPr-peptide eluate that still 5 
harbors eAf1521 protein. C, MWCO flow-throughs of unbound, free eAf1521. The Amicon-100K filter was 6 
a filter control where it was expected that eAf1521 would not be retained.  7 
Supplemental Figure S2. Molecular weight cut-off (MWCO) filters impact HeLa peptide / proteome 8 
recovery. A, Representative total ion current (TIC) chromatograms from each peptide sample type. B, 9 
The average normalized protein abundances for each MWCO workflow. C, Principle component analysis 10 
of the resulting proteome data demonstrating the Micron (UltraCell) filter most resembles the input 11 
peptide sample. 12 
Supplemental Figure S3. Instrument acquisition methods and samples analyzed. 13 
Supplemental Figure S4. Proteome Discoverer 2.4 exports of a mouse liver ADPr peptide analyzed 14 
by HCD, CID or ETD on the Lumos. The HCD and CID SELENBP1/2 ADPr spectra are also in Figure 15 
2. All fragment ions (b/y-ion and p-ion series) except the m-ions are annotated in PD2.4.  16 
Supplemental Figure S5. The m-ion and p-ion series score distributions at varying HCD and CID 17 
collision energies. A, m-ion score breakdown for each instrument and collision energy. B, Fragment p-18 
ion, precursor P-ion and the total p-series scores distributions for each instrument and collision energy. 19 
C, The various p-series scores (median) vs. collision energy% and the XCorr (median) vs. collision 20 
energy% for non-ADPr and ADPr spectra identified from MARylated peptide samples. D, The individual 21 
m-ion score proportions (median) vs. collision energy%. E, Direct infusion of AMP (m6) demonstrating 22 
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Supplemental Figure S6. Individual precursor P-ion distributions at select HCD or CID collision 1 
energies. Histograms are 50-bins. 2 
Supplemental Figure S7. The effect of precursor charge on XCorr vs. p-series scores. A, Fragment 3 
p-ions (upper panels) or precursor P-ions (lower panels) B, The analysis of precursor mass [MH+] 4 
distribution when the p-series scores are compared to XCorr. 5 
Supplemental Figure S8. Mouse liver and spleen respond to IFN- injection. A, PARP14 mRNA 6 
expression profile on the human protein atlas database. B, C, Cytokines (upper panels) and PARPs 7 
mRNA responses to 4 hours IFN-: 100 K units/mouse for liver (B) and spleen (C). Saline expression = 8 
1.0. t-test with Welch’s correction; Saline vs IFN-. ***p<0.001, **p<0,01, *p<0.05. 9 
Supplemental Figure S9. Mouse liver and spleen anti-ADP-ribosylation Western blots analysis. A, B, 10 
liver and C, D, spleen. N=2 mice organs per time point. The red box in the gel corresponds to the region 11 
used for quantification by ImageJ (B, D). 12 
Supplemental Figure S10. Validation of a PARP14 ADPr peptide from Figure 7. A, HCD (27.5% CE) 13 
spectrum derived from a spleen no treatment control sample indicating histidine as the acceptor site. B 14 
and C, PRM scans from EThcD (B) and HCD 20% CE (C) reveal serine to be the correct acceptor site 15 
and not histidine. 16 
Supplemental Figure S11. Rank2 spectrum is correct for FABP1 in Figure 7. A and B, the same 17 
HCD scan with SEQUEST-HT rank1 and rank2 acceptor site assignments. C, The corresponding EThcD 18 
scan. 19 
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Supplemental Table S1. ADP-ribosyl peptide fragment ions. 22 
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Supplemental Table S4. Protein lists from Figure 6B Venn diagrams. 2 
Supplemental Table S5. IFN--induced changes to the liver proteome. 3 
Supplemental Table S6. IFN--induced changes to the spleen proteome. 4 
Supplemental Table S7. IFN--induced changes to mouse spleen ADPr peptides 5 
Supplemental Table S8. IFN--induced changes to mouse liver ADPr peptides. 6 

































































 An annotation method to identify and score ADP-ribosyl peptide MS2 spectra 
 The m-ion series score monitors the dissociation properties of the ADP-ribosyl 
modification  
 The p-ion series score monitors the dissociations properties of the backbone 
peptide plus residual ADP-ribosyl fragment 
 The p-ions provide support to increase the number of reportable ADP-ribosyl 









ADP-ribosyl peptides exhibit complex HCD-derived MS2 spectra that comprise peaks 
corresponding to the complete or partial dissociation of the ADP-ribosyl moiety itself (m-ions); 
and peaks corresponding to the residual modification on the intact peptide (P-ion) that in turn 
undergoes further dissociation to produce peptide fragments (p-ions). Our novel workflow 
annotates and scores these unique ADP-ribose fragments not recognized by standard 
annotation methods. This workflow increased the number of reportable ADP-ribosyl peptides 
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